Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
61 hedge funds and large institutions have $237M invested in Adverum Biotechnologies in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 22 closing their positions.
354% more capital invested
Capital invested by funds: $52.2M → $237M (+$185M)
73.86% more ownership
Funds ownership: 6.86% → 80.72% (+74%)
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
2% more funds holding
Funds holding: 60 → 61 (+1)
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
87% less call options, than puts
Call options by funds: $390K | Put options by funds: $2.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$30.5M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$22.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$22.8M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$16.3M |
| 5 |
VA
VR Adviser
New York
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.12M |
| 2 |
CC
Commodore Capital
New York
|
-$5.21M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.02M |
| 4 |
Goldman Sachs
New York
|
-$3.43M |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.35M |
ADVM Hedge Fund Activity: Q1 2024 in Review
61 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2024, worth a combined $237M — up 354% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ADVM positions and 22 closed out — a net gain of 1 holder — while 19 added to existing stakes and 15 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $30.5M. The largest seller was Morgan Stanley, cutting an estimated $7.12M.
- 61 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2024, up from 60 in Q4 2023.
- Funds reported $237M of Adverum Biotechnologies stock for Q1 2024, up 354% quarter-over-quarter.
- 23 funds opened new Adverum Biotechnologies positions in Q1 2024 and 22 closed out, a net change of +1 holder.
- The largest Adverum Biotechnologies buyer in Q1 2024 was TCG Crossover Management, an estimated $30.5M added.
- The largest Adverum Biotechnologies seller in Q1 2024 was Morgan Stanley, an estimated $7.12M sold.
Based on aggregated 13F filings for Q1 2024.